Atorvastatin therapy was found to be ineffective in reducing atherosclerosis progression in children and adolescents with systemic lupus erythematosus (SLE). Results of the Atherosclerosis Prevention in Pediatric Lupus Erythematosus Trial show that the statin therapy did trend toward positive effect of treatment and may benefit patients with more severe SLE who were not included in the trial.